<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03151447</url>
  </required_header>
  <id_info>
    <org_study_id>FDRT-BC005</org_study_id>
    <nct_id>NCT03151447</nct_id>
  </id_info>
  <brief_title>Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Metastatic Triple Negative Breast Cancer</brief_title>
  <official_title>A Phase I Trial of Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Patients With Metastatic Triple Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and tolerance of Stereotactic Body&#xD;
      Radiation Therapy Combined With Anti-PD-1 Antibody in Patients in Metastatic Triple Negative&#xD;
      Breast Cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to evaluate the safety and tolerance of Stereotactic Body&#xD;
      Radiation Therapy Combined With Anti-PD-1 Antibody（JS001） in Patients With Metastatic Triple&#xD;
      Negative Breast Cancer&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">March 6, 2017</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Stereotactic Body Radiation Therapy With Concurrent Anti-PD1antibody (JS001) injected intravenously 120mg or 240mg or 360mg until disease progresses or unacceptable tolerability occurs</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment</measure>
    <time_frame>3 years</time_frame>
    <description>The incidence and severity of adverse events, clinically significant abnormal laboratory results, ECG and vital signs were assessed according to CTCAE4.03</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>SBRT in combined with anti-PD-1 antibody</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive stereotactic body radiation therapy to metastatic lesions of liver, lung, bone, brain or lymph nodes and concurrent anti-PD-1 antibody treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>stereotactic body radiation therapy</intervention_name>
    <description>In patients with metastatic triple negative breast cancer, stereotactic body radiation therapy will be combined with anti-PD-1 antibody.&#xD;
Stereotactic body radiation therapy: SBRT is delivered to 1~5 measurable metastatic lesions of liver, lung, bone, brain or lymph nodes in limited fractions .&#xD;
Anti-PD-1 treatment: anti-PD-1 antibody (JS001) is injected intravenously 120mg or 240mg or 360mg every two weeks.</description>
    <arm_group_label>SBRT in combined with anti-PD-1 antibody</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must be able to understand and willing to sign a written informed consent&#xD;
             document.&#xD;
&#xD;
          -  Patients with advanced triple-negative breast cancer (histologically or cytologically&#xD;
             confirmed invasive breast carcinoma with estrogen receptor negative, progesterone&#xD;
             receptor negative, human epidermal growth factor receptor 2 negative).&#xD;
&#xD;
          -  Patients must have progressed on or been intolerant of at least prior first-line&#xD;
             systemic treatment with anthracycline and/or taxane drugs for metastatic disease.&#xD;
             There are no any routine regimens.&#xD;
&#xD;
          -  At least 5-8 pieces of pathological tissue can be provided (for the detection of PD-L1&#xD;
             expression and the infiltrating lymphocytes).&#xD;
&#xD;
          -  Patients must have at least one metastatic lesion with diameter&gt; 1 cm that is amenable&#xD;
             to SBRT, as determined by radiation oncologist.&#xD;
&#xD;
          -  Patients must be able to withstand the radiotherapy process, such as maintaining the&#xD;
             position, etc.&#xD;
&#xD;
          -  Patients must have at least 2 measurable lesions (based on RECIST V1.1);&#xD;
&#xD;
          -  Female aged 18 to 75 years old are eligible.&#xD;
&#xD;
          -  Weight ≥40kg&#xD;
&#xD;
          -  Life expectancy ≥6 months&#xD;
&#xD;
          -  ECOG performance status score of 0 or 1&#xD;
&#xD;
          -  There must be at least 4 weeks since the last radiotherapy, chemotherapy, hormone&#xD;
             therapy and molecular targeted therapy. Patients must have recovered from any toxicity&#xD;
             related to prior therapy and the toxicity should be less than or equal to grade 1&#xD;
             (according to CTCAE 4.03) or returned to baseline.&#xD;
&#xD;
          -  A systemic medication (such as corticosteroids) with an immunosuppressive dose&#xD;
             (prednisone&gt; 10 mg/d or equivalent dose) must have been discontinued for at least 2&#xD;
             weeks before the initiation of the study drug.&#xD;
&#xD;
          -  Surgeries requiring general anesthesia must have been completed for at least 4 weeks&#xD;
             before the initiation of the study drug. Surgeries requiring local anesthesia or&#xD;
             epidural anesthesia must have been completed for at least 72 hours and the patients&#xD;
             have recovered from these surgeries. Skin biopsy that needs local anesthesia must have&#xD;
             been completed for at least 1 hour.&#xD;
&#xD;
          -  The Laboratory test results must meet the following criteria:&#xD;
&#xD;
               1. neutrophils ≥1.5×109/L&#xD;
&#xD;
               2. Platelets ≥100×109/L&#xD;
&#xD;
               3. Hemoglobin ≥90g/L (no blood transfusion within past 14 days)&#xD;
&#xD;
               4. Serum Cr ≤1×ULN, endogenous creatinine clearance rate &gt;50ml/min (Cockcroft-Gault&#xD;
                  formula)&#xD;
&#xD;
               5. AST ≤2.5×ULN, ALT ≤2.5×ULN; both ALT and AST ≤5×ULN if there are liver metastasis&#xD;
&#xD;
               6. Total bilirubin ≤ 1.5 × ULN (except for patients with Gilbert syndrome, the total&#xD;
                  bilirubin of those patients must be &lt;51.3μmol/L)&#xD;
&#xD;
               7. TSH, FT3, FT4 are within ± 10% of the normal range.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence with active central nervous system (CNS) metastases. Patients can be included&#xD;
             if the CNS metastasis can be treated and the neurological symptoms can be restored to&#xD;
             a level of ≤1 degree of CTCAE (except for residual signs or symptoms associated with&#xD;
             CNS treatment) for at least 2 weeks before the enrollment. In addition, patients must&#xD;
             have not be treated with a corticosteroid, or just be treated with a stable dose of ≤&#xD;
             10 mg prednisone/day (or equivalent dose) or with a dose reduced to 10 mg&#xD;
             prednisone/day;&#xD;
&#xD;
          -  Patients with cancerous meningitis&#xD;
&#xD;
          -  The same part of body has been irradiated previously;&#xD;
&#xD;
          -  Patients with active, known or suspected autoimmune diseases. Patients with the&#xD;
             following conditions can be selected: vitiligo, type I diabetes, residual thyroid&#xD;
             dysfunction caused by autoimmune thyroiditis that just need hormone replacement&#xD;
             therapy, or diseases that will not relapse without external stimulating factors;&#xD;
&#xD;
          -  Any prior immune checkpoint inhibition treatment with anti-PD-1/PD-L1 /PD-L2 antibody&#xD;
             or anti-CTLA-4 antibody (or any other antibody acting on the T cell co-stimulus or&#xD;
             checkpoint pathway)&#xD;
&#xD;
          -  Evidence of active pulmonary tuberculosis (TB). Patients diagnosed with active&#xD;
             tuberculosis infection within 1 year should be excluded even if they have been&#xD;
             treated. Patients diagnosed with active tuberculosis infection for more than 1 year&#xD;
             must be excluded unless previous anti-tuberculosis treatment is effective;&#xD;
&#xD;
          -  Positive test of immunodeficiency virus (HIV) or acquired immunodeficiency syndrome&#xD;
             (AIDS);&#xD;
&#xD;
          -  Complications that require immunosuppressive drugs or systemic or topical&#xD;
             corticosteroids with immunosuppressive doses;&#xD;
&#xD;
          -  Prior treatment of other study drug within past 28 days, or though the internal is&#xD;
             more than 28 days, precious study drug is still in the 5 half-life periods;&#xD;
&#xD;
          -  Inoculation of any anti-infective vaccine (such as influenza vaccine, varicella&#xD;
             vaccine, etc.) within past 4 weeks;&#xD;
&#xD;
          -  Pregnancy and breastfeeding&#xD;
&#xD;
          -  Patients that can't receive intravenous puncture and/or venous access;&#xD;
&#xD;
          -  History of other medical, psychological or social reasons as determined by the&#xD;
             investigator;&#xD;
&#xD;
          -  History of symptomatic interstitial lung disease or other conditions that may cause&#xD;
             confusion when discovering or managing suspicious drug-related lung toxicity;&#xD;
&#xD;
          -  Prior traditional Chinese medicine therapy with antitumor activity within past 2&#xD;
             weeks;&#xD;
&#xD;
          -  Prior therapy with monoclonal antibodies within past 3 months (except for locally&#xD;
             administration);&#xD;
&#xD;
          -  History of other malignant tumors. (Except for non-melanoma skin cancer and the&#xD;
             following carcinomas in situ: bladder, stomach, colon, endometrium, cervical /&#xD;
             dysplasia, melanoma or breast cancer). Patients who have obtained complete response&#xD;
             for at least 2 years prior to enrollment and don't need receive other treatment should&#xD;
             be included;&#xD;
&#xD;
          -  Underlying medical conditions, according to the investigator, that would increase the&#xD;
             risks of study drug administration or obscure the interpretation of adverse events;&#xD;
&#xD;
          -  Chronic hepatitis B (HBs Ag positive) or chronic hepatitis C (HCV antibody positive);&#xD;
&#xD;
          -  Patients with known sensitivity or allergy to any components of humanized anti-PD-1&#xD;
             antibody.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiaomao Guo</last_name>
    <phone>+86</phone>
    <email>guoxm1800@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>LI Zhang</last_name>
    <phone>+8613818119034</phone>
    <email>zhangliaaa111@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaomao Guo, Ph.D</last_name>
      <email>guoxm1800@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>May 4, 2017</study_first_submitted>
  <study_first_submitted_qc>May 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2017</study_first_posted>
  <last_update_submitted>May 11, 2017</last_update_submitted>
  <last_update_submitted_qc>May 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Xiaomao Guo</investigator_full_name>
    <investigator_title>The President of Fudan University Shanghai Cancer Center</investigator_title>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Anti-PD1 Antibody</keyword>
  <keyword>Stereotactic Body Radiation Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

